The primary objective of the Harvard Cancer Consortium (HCC) Brain Cancer Specialized Program of Research Excellence (SPORE) is to improve the standard of care for adult and pediatric gliomas through the use of targeted therapies. To this end, basic scientists from Harvard Medical School have joined clinical and translational investigators from Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, and Massachusetts General Hospital. This initiative is supported by central cores for pathology, biostatistics and computational biology, and administration, and it includes career and developmental programs.
SPORE
Brain Cancer
Specialized Programs of Research Excellence